Navigation Links
Reportlinker Adds Pharmaceutical Key Trends 2010
Date:12/14/2010

NEW YORK, Dec. 14, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical Key Trends 2010

http://www.reportlinker.com/p0186184/Pharmaceutical-Key-Trends-2010.html

IntroductionPharma faces a number of key resistors to growth including the impending 2011 patent cliff which is set to erode $78 billion in global branded sales from drugs facing patent expiry over the 201014 period (plus $32 billion from continued erosion of already expired brands). Price cuts, reimbursement restrictions and growing regulatory pressure are further set to limit sales growth going forward.

Scope* Overview of the key drivers and resistors facing Pharma, Biotech and generics players out to 2014

* Analysis of recent regulatory changes in the US, EU and emerging markets and their impact on pricing and reimbursement, drug development and marketing

* Examination of key global and country-specific issues facing both biosimilars and generics players

* Assessment of the impact of the global economic downturn on the Pharma and Biotech sectors and their respective counter strategies

HighlightsAnnual sales growth of pharmaceuticals in the emerging markets is already double-digit, providing a key opportunity for Pharma. Revenue streams in these markets can be derived from launching branded off-patent drugs, branded generics, and local brands owned or licensed by the acquiring pharma company.

Pharma is moving away from the "me-too" and increasingly genericized primary care market towards more high value biologic therapies in secondary care as well as more niche markets; markets with little or no existing competition, and which despite their smaller size (in terms of patient numbers) are still commercially attractive.

To maintain profitability in the face of slowing sales to 2014, pharma companies have implemented a number of cost-cutting measures (in addition to strategic repositioning and diversification strategies) in order to boost profitability going forward.

Reasons to Purchase* Examine the combined prescription drug sales forecasts for the top 50 Pharma out to 2014 by molecule type, product source, geography and therapy area

* Identify the key factors impacting Pharma's R&D productivity as well as the solutions companies are implementing to strengthen their R&D efforts

* Assess key drivers behind Pharma's M&A activity and its role in boosting profits by opening up new access to new markets as well as cutting costs

ABOUT DATAMONITOR HEALTHCARE 2

About the Healthcare Strategic Analysis Team 2

1. About this report 3

Data sourcing – the PharmaVitae Explorer database 3

Chapter structure 4

Glossary 5

Related reports 5

Upcoming related reports 5

2. Executive Summary 6

Key drivers and resistors facing Pharma 6

Resistors for Pharma 7

Drivers for Pharma 14

Neutral for Pharma 23

Key drivers and resistors facing generics and biosimilars companies 26

Key drivers and resistors facing Biotech 28

3. Healthcare Systems and Regulations 32

Expansion of healthcare provision top of the agenda of many countries 32

US health reform set to change the country's healthcare landscape 36

The FDA is set on restoring its reputation 62

Drug prices suffer in Japan 69

Five major EU markets – cost-containment pressures mount 72

EU legislation focused on streamlining regulatory processes 80

New healthcare initiatives in the emerging markets are tackling growing costs 83

Brazil's ANVISA may hamper the domestics growth of multinational pharma companies 85

Russia enhances regulations to boost growth of the domestic pharma industry 87

India tackles growing healthcare expenditure by tightening price controls and increasing access to generic drugs 90

China's healthcare reforms will expand the domestic market but may create challenges for foreign companies 92

4. Generics and Biosimilars 95

The generics market 96

The biosimilars market 117

5. Recession and Recovery 131

Appendix

Pharmaceutical Key Trends 2010 DMHC2599

Largely insulated from the recession Pharma's key threat is the patent cliff 131

Biotech emerges from its funding crisis 138

6. Prescription Drug Market Outlook 146

Definitions – launch, core, expiry 146

Drivers and resistors for sales growth of the top 50 pharma companies out to 2014 146

7. Research and Development 164

Pharma continues to battle with R&D issues 164

Pharma's R&D cost-cutting exercise is only a short-term solution 168

Pharma's late-stage deal activity set to increase to help offset the patent cliff 170

Pharma's level of early-stage R&D collaboration intensifies 171

Outsourcing set to rise following initial cost-cutting exercises implemented during the economic downturn 173

Pharma sharpens its focus on secondary care indications through high value biologic therapies as the patent cliff looms 175

Personalized medicine and stem cell technology are key strategies in the commercialization of niche indications 183

Pharma embraces low cost late-stage lifecycle management strategies 187

8. Mergers and Acquisitions 192

M&A will remain a central strategy for Pharma 192

M&A deals to increase scale and cut costs 196

M&A deals to target high growth therapeutic markets 199

M&A deals to target high growth geographic markets 201

M&A deals to increase pharma focus or diversify into other healthcare markets 205

9. Bibliography 212

Executive Summary 212

Healthcare Systems and Regulations 212

Generics and Biosimilars 223

Recession and Rrecovery 232

Prescription Drug Market Outlook 235

Research and Development 235

Mergers and Acquisitions 241

APPENDIX 244

Exchange rates 244

US healthcare reform model 245

About Datamonitor 253

Appendix

Datamonitor consulting 254

Disclaimer 256

To order this report:Pharmaceutical Industry: Pharmaceutical Key Trends 2010

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 18, 2017  Magnetic Insight Inc., leader ... into an agreement with inviCRO LLC to develop ... imaging system based on inviCRO,s VivoQuant™ visualization and ... as a complete MPI solution package with the ... or cell imaging in vivo. MPI ...
(Date:1/19/2017)... NEW YORK , Jan. 18, 2017 ... USD 1,669.40 billion by 2021 from USD 1,179.20 billion ... forecast period. Increasing prevalence of chronic diseases, increasing ... are the factors driving the growth of this market. ... biosimilars and generic drugs offer significant growth opportunities for ...
(Date:1/19/2017)... , Jan. 18, 2017 ... Summary GlobalData,s new report, "South Korea Insulin Delivery ... the South Korea Insulin Delivery market. The report provides ... and average prices (USD) within market segments - Insulin ... Accessories. The report also provides company shares and ...
Breaking Medicine Technology:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... of a doctor who administered fillers that resulted in severe facial disfiguration. After ... was taken on by doctors at UCLA Medical Center, who removed the substances ...
(Date:1/19/2017)... ... 2017 , ... Workrite Ergonomics announced this week the launch ... panel system was designed to deliver the ideal blend of acoustic and visual ... the visual privacy required to maintain concentration levels and increase productivity. The tranquility ...
(Date:1/19/2017)... ... 2017 , ... Sam & Associates Insurance Agency, a full service firm providing ... California Bay Area, is launching a charity drive to raise awareness of heart disease ... the primary killer of adult men and women in America, and is responsible for ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... agency which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating ... lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone ...
(Date:1/19/2017)... ... 19, 2017 , ... Creative messages to prevent distracted driving ... Impact Teen Drivers and California Casualty. Entries from students aged 14-22 can be ... $15,000 will be awarded for the best peer-to-peer messages sharing solutions to reckless ...
Breaking Medicine News(10 mins):